I agree. The increased emphasis on generics and especially biogenerics and the embracing a discovery model that emphasizes rare diseases are both part of the business model Vasella has promoted.
However, PFE seems to suffer from from being late to the game as witnessed by them recently losing out on Ratiopharm to TEVA. I also think NVS was correct to try to avoid commodity type pricing by focusing on harder to manufacture generics. However, I have been dismayed by the slow pace of adoption of biogeneric legislation. This market has not materialized nearly as quickly as I had hoped. Amazing that we as a country lament the cost of health care but then move at glacial speed to correct obvious points where cost savings can be gained.
Hopefully we see movement on implementing biogenerics in the near future. I'd hate to think NVS (and MNTA) will have to sue FDA (as was done with omnitrope) to force them to move.
Market Data 
Markets 
AI
